Elevated Lipoprotein-Associated Phospholipase A2 Is Associated With Intracranial Atherosclerosis.
Elevated Lipoprotein-Associated Phospholipase A2 Is Associated With Intracranial Atherosclerosis.
复制标题
DOI：
10.3389/fneur.2022.858302
复制
发表时间：
2022
影响因子：
3.4
通讯作者：
Cao, Guodong
中科院分区：
文献类型：
--
作者：
Wang, Yuan;Liu, Gang;Song, Haiqing;Cao, Catherine;Ji, Xunming;Cao, Guodong
关键词：
脂蛋白相关磷脂酶A2(Lp-PLA2)是动脉粥样硬化斑块发病机制中的一种炎性因子，与缺血性卒中的风险增加有关。Lp-PLA2是否与急性缺血性卒中(AIS)的狭窄亚型相关尚无研究。126例符合条件的AIS患者分为4组：(1)无脑动脉狭窄(NCS)；(2)颅内动脉狭窄(ICAS)；(3)颅外动脉狭窄(ECAS)；(4)颅内外动脉联合狭窄(IECS)。评估血清Lp-PLA2水平与狭窄亚型之间的关系。与NCS组和IECS组相比，ICAS组血脂异常的发生率较低(分别为35.3%和70%，P=0.001)，并且比ECAS组更容易出现症状(分别为76.5%和43.8%，P=0.014)。颈内动脉组Lp-PLA2水平为112.2±66.8mgg/L，高于正常对照组、体外循环组和体外循环组(分别为81.70±38.5、106.1±57.8、89.3±52.2μg/L，P=0.025)。在Lp-PLA2水平的第三和第四四分位数中，颈内动脉组的狭窄发生率高于其他三组(第三Q：50.0%对3.1%对28.1%对18.8%，p=0.002；第四Q：48.4%对16.1%对25.8%对9.7%，p=0.014)。ICAS组中狭窄程度较重或严重的患者Lp-PLA2水平较高。与有颈动脉狭窄或无狭窄的AIS患者相比，合并ICAS的AIS患者Lp-PLA2水平升高与风险增加有差异。Lp-PLA2可能成为ICAS的一个有前景的生物标志物和潜在的治疗靶点。
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory factor in the pathogenesis of atherosclerotic plaque and is associated with an increased risk of ischemic stroke. Whether Lp-PLA2 is associated with stenosis subtypes in acute ischemic stroke (AIS) has not been investigated. A total of 126 eligible AIS patients were divided into four groups: (1) no cerebral artery stenosis (NCS); (2) intracranial artery stenosis (ICAS); (3) extracranial artery stenosis (ECAS); and (4) combined intracranial and extracranial artery stenosis (IECS). Associations between serum Lp-PLA2 levels and the stenosis subtypes were assessed. The ICAS group had a lower frequency of dyslipidemia as compared to the NCS group and the IECS group (35.3% vs. 70% vs. 71.8%, respectively, p = 0.001) and was more likely to be symptomatic than the ECAS group (76.5% vs. 43.8%, respectively, p = 0.014). Lp-PLA2 levels in the ICAS group were 112.2 ± 66.8 μg/L which are, higher than those in the NCS, ECAS, and IECS groups (81.7 ± 38.5, 106.1 ± 57.8, 89.3 ± 52.2 μg/L, respectively, p = 0.025). In the third and fourth quartiles of Lp-PLA2 levels, stenosis had occurred more frequently in the ICAS group than in the other three groups (third Q: 50.0% vs. 3.1% vs. 28.1% vs. 18.8%, p = 0.002; fourth Q: 48.4% vs. 16.1% vs. 25.8% vs. 9.7%, p = 0.014). Lp-PLA2 levels were higher in patients with more or severe stenosis in the ICAS group. Elevated Lp-PLA2 levels were differentially associated with increased risk in AIS patients with ICAS compared to those with ECAS or no stenosis. Lp-PLA2 may be a promising biomarker and potential therapeutic target for ICAS.
登录
查看更多内容
影响因子：
8.3
作者：
Meschia JF;Bushnell C;Boden-Albala B;Braun LT;Bravata DM;Chaturvedi S;Creager MA;Eckel RH;Elkind MS;Fornage M;Goldstein LB;Greenberg SM;Horvath SE;Iadecola C;Jauch EC;Moore WS;Wilson JA;American Heart Association Stroke Council;Council on Cardiovascular and Stroke Nursing;Council on Clinical Cardiology;Council on Functional Genomics and Translational Biology;Council on Hypertension
通讯作者：
Council on Hypertension
影响因子：
5.3
作者：
Delgado, Pilar;Chacon, Pilar;Montaner, Joan
通讯作者：
Montaner, Joan
影响因子：
168.9
作者：
Qureshi, Adnan I.;Caplan, Louis R.
通讯作者：
Caplan, Louis R.
影响因子：
9.9
作者：
Lin, Jinxi;Zheng, Hongwei;Wang, Yongjun
通讯作者：
Wang, Yongjun
影响因子：
8.3
作者：
Elkind, Mitchell S. V.;Leon, Vladimir;Sacco, Ralph L.
通讯作者：
Sacco, Ralph L.